CaDAnCe-101: A phase 1 and 2 trial of the treatment BGB-16673 in people with B-cell lymphomas

This trial aims to assess the treatment BGB-16673 in adults with B-cell lymphomas.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05006716

Trial aim and background  

The aim of this trial is to establish the best dose of the treatment BGB-16673 and then to test how safe and effective it is at this dose.

BGB-16673 is a type of targeted treatment called a BTK targeted protein degrader. BTK is part of a pathway that helps B-cells to stay alive and divide. BGB-16673 breaks down BTK which can make B-cells die, or stop them from dividing.

Part of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future. 

Who can enter 

People with the following lymphomas may be eligible for this trial:

Locations 

Recruitment is taking place at the following UK locations:

  • Derriford Hospital, Plymouth
  • Edinburgh Cancer Centre, Edinburgh
  • Freeman Hospital, Newcastle
  • Nottingham University Hospitals NHS Trust, Nottingham
  • St James’s University Hospital, Leeds

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT05006716

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.